A long-term latent reservoir for HIV-1: discovery and clinical implications.
about
Valproic acid and HIV-1 latency: beyond the sound bite.Akt inhibitors as an HIV-1 infected macrophage-specific anti-viral therapyCerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatmentSIVsm quasispecies adaptation to a new simian host.A Modified P1 Moiety Enhances in vitro Antiviral Activity against Various Multi-Drug-Resistant HIV-1 Variants and in vitro CNS Penetration Properties of a Novel Nonpeptidic Protease Inhibitor, GRL-10413ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremiaHIV quasispecies dynamics during pro-active treatment switching: impact on multi-drug resistance and resistance archiving in latent reservoirsHepatitis C viral evolution in genotype 1 treatment-naïve and treatment-experienced patients receiving telaprevir-based therapy in clinical trialsLimits on replenishment of the resting CD4+ T cell reservoir for HIV in patients on HAARTLow-level HIV-1 replication and the dynamics of the resting CD4+ T cell reservoir for HIV-1 in the setting of HAART.Modeling latently infected cell activation: viral and latent reservoir persistence, and viral blips in HIV-infected patients on potent therapy.Lack of pharmacokinetic interaction between amdoxovir and reduced- and standard-dose zidovudine in HIV-1-infected individuals.Suppression of virus load by highly active antiretroviral therapy in rhesus macaques infected with a recombinant simian immunodeficiency virus containing reverse transcriptase from human immunodeficiency virus type 1.Missing data on the estimation of the prevalence of accumulated human immunodeficiency virus drug resistance in patients treated with antiretroviral drugs in north america.Novel protease inhibitors (PIs) containing macrocyclic components and 3(R),3a(S),6a(R)-bis-tetrahydrofuranylurethane that are potent against multi-PI-resistant HIV-1 variants in vitro.Primary human mammary epithelial cells endocytose HIV-1 and facilitate viral infection of CD4+ T lymphocytes.Persistence of hepatitis B virus covalently closed circular DNA in hepatocytes: molecular mechanisms and clinical significance.Pharmaceutical approaches to eradication of persistent HIV infection.A randomized, placebo-controlled trial of abacavir intensification in HIV-1-infected adults with virologic suppression on a protease inhibitor-containing regimen.Administration of fludarabine-loaded autologous red blood cells in simian immunodeficiency virus-infected sooty mangabeys depletes pSTAT-1-expressing macrophages and delays the rebound of viremia after suspension of antiretroviral therapyA novel tricyclic ligand-containing nonpeptidic HIV-1 protease inhibitor, GRL-0739, effectively inhibits the replication of multidrug-resistant HIV-1 variants and has a desirable central nervous system penetration property in vitro.A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro.Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4'-ethynyl-2-fluoro-2'-deoxyadenosine.Intensifying Antiretroviral Therapy With Raltegravir and Maraviroc During Early Human Immunodeficiency Virus (HIV) Infection Does Not Accelerate HIV Reservoir Reduction.Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy.The role of HIV integration in viral persistence: no more whistling past the proviral graveyard.Anti-viral opportunities during transcriptional activation of latent HIV in the host chromatin.GRL-0519, a novel oxatricyclic ligand-containing nonpeptidic HIV-1 protease inhibitor (PI), potently suppresses replication of a wide spectrum of multi-PI-resistant HIV-1 variants in vitro.Development of an optimized dose for coformulation of zidovudine with drugs that select for the K65R mutation using a population pharmacokinetic and enzyme kinetic simulation model.Production of a dendritic cell-based vaccine containing inactivated autologous virus for therapy of patients with chronic human immunodeficiency virus type 1 infection.Prolonged persistence of a novel replication-defective HIV-1 variant in plasma of a patient on suppressive therapyGRL-04810 and GRL-05010, difluoride-containing nonpeptidic HIV-1 protease inhibitors (PIs) that inhibit the replication of multi-PI-resistant HIV-1 in vitro and possess favorable lipophilicity that may allow blood-brain barrier penetration.Modeling HIV persistence, the latent reservoir, and viral blips.Effectiveness of option B highly active antiretroviral therapy (HAART) prevention of mother-to-child transmission (PMTCT) in pregnant HIV women.Surveillance programs for detection and characterization of emergent pathogens and antimicrobial resistance: results from the Division of Infectious Diseases, UNIFESP.Role of macrophages in HIV infection and persistence.Analysis of the roles of HIV-derived microRNAs.Mapping the architecture of the HIV-1 Tat circuit: A decision-making circuit that lacks bistability and exploits stochastic noise.Contributions of HIV-1 Nef to immune dysregulation in HIV-infected patients: a therapeutic target?Cyclin-dependent kinases as therapeutic targets for HIV-1 infection.
P2860
Q24530234-41B7A9E8-5A9A-411E-BA99-33C74179771EQ24655510-78BD8840-769C-4EB9-8EC7-65C3062E2225Q24814874-2C19EAAD-0349-4046-8CF8-6182A01BC872Q24817181-B7D4D9EA-8A01-4893-A0EE-83AC17E3401FQ27728053-5530C6E2-B2EF-4049-BF3B-C1DEA97D0DDCQ28469175-6EAF4324-833B-413C-B1F0-06D134B61800Q28477500-91AC6D16-DCBB-4A59-8C02-A67B930972E6Q28730617-BE7FD713-D1AF-44FD-8D1B-2E101F96734AQ33296883-A901189A-0169-48C7-A34A-F098BA33FA13Q33313038-5F1BFE72-063E-48E7-80A6-A44B041DFB24Q33510903-832C79BF-E039-4451-97EA-52B2546717FEQ33676340-F5469F5B-0BC9-4A55-8333-E3BD01B70534Q33843148-405C7EC4-9322-4A41-8C18-4404D427AFF2Q33981074-1F90E7EC-A8A8-4E93-AC6F-DE246EA319FEQ34045363-758910BF-D18D-4688-B68F-CBEB9496B620Q34178300-FC182166-F801-445F-9990-17EE936DB848Q34289969-23F34251-3050-4750-B719-D6B440FB5B7EQ34941973-C458EE0D-2540-4990-BA4D-8E0D1AE04B50Q35024683-4B9461C8-E7CA-4753-A106-36084C98843EQ35139258-9C215121-0DDE-446E-82D1-DEE49A5F91A9Q35386013-5E3AA8F1-FB62-49DA-BFA0-D2774B1F1184Q35840811-AC8D9C2C-6851-4198-BA77-632845C526E1Q35912640-61283212-9A8A-4842-AED6-A8BE35F3CCFBQ36210055-01901D6A-A4AD-4DFD-8C6F-2CE3918853F7Q36499290-B4CC3542-3E3F-4969-A211-10B73D12CDDCQ36515181-D5CD4C23-7951-4FB7-8FEF-0EF78563705DQ36632210-3A9E7D0E-190F-4E9B-A427-10C5C972799CQ36785919-DE5E318E-2647-44DD-95CA-33352857D3C5Q36993425-5696C6F4-5A68-4244-9661-856445C5E1A2Q37099222-293BB5A1-19ED-4341-9580-46E3076D6496Q37272747-64D91755-A7EE-4EE0-8467-F522B6400016Q37335823-5531E2ED-6711-4009-A30B-0983280550FCQ37365718-C72E5438-42D8-4338-A2CA-00015AB072F3Q37503621-E67755B4-01F5-49F9-99E8-48043E5412D6Q37590197-56EC75AF-F811-4E30-9E99-F71CDC09A6B7Q37755250-FE68B6B8-9271-4361-8E7D-94F7663E7BBEQ37816443-8644E587-F328-42E1-8959-630C4CE06790Q37822089-5DC0E649-CBB7-4AB9-81C3-F8208F4B705FQ38130717-6C41869E-BCC1-4567-B83E-77DAAA243DDCQ38995028-7F7BB93F-1079-4EE0-ACD7-FE9EF04FC64A
P2860
A long-term latent reservoir for HIV-1: discovery and clinical implications.
description
2004 nî lūn-bûn
@nan
2004 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
A long-term latent reservoir for HIV-1: discovery and clinical implications.
@ast
A long-term latent reservoir for HIV-1: discovery and clinical implications.
@en
type
label
A long-term latent reservoir for HIV-1: discovery and clinical implications.
@ast
A long-term latent reservoir for HIV-1: discovery and clinical implications.
@en
prefLabel
A long-term latent reservoir for HIV-1: discovery and clinical implications.
@ast
A long-term latent reservoir for HIV-1: discovery and clinical implications.
@en
P356
P1476
A long-term latent reservoir for HIV-1: discovery and clinical implications.
@en
P2093
Janet D Siliciano
P356
10.1093/JAC/DKH292
P407
P577
2004-05-26T00:00:00Z